A Novel Risk Assessment Model to Predict Venous Thromboembolism (VTE) in Cancer Inpatients: The Canclot Score by Dana E. Angelini, M. Todd Greene, Julie.

Slides:

Advertisements

Similar presentations

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.

Advertisements

Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13): December 15, 2008 ©2008 by American Society of Hematology.

Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.

Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study by Cheng E. Chee, Aneel A. Ashrani,

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.

Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses by Klaus Juul, Anne Tybjærg-Hansen, Rolf Steffensen, Steen Kofoed, Gorm Jensen, and.

by Hugoline G. de Haan, Irene D. Bezemer, Carine J. M

Do HSCs divide asymmetrically?

Central venous line–related thrombosis in children: association with central venous line location and insertion technique by Christoph Male, Peter Chait,

by Robert F. Todd, Scott D. Gitlin, Linda J. Burns, and

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,

TCR-MHC-peptide(s): in vivo veritas

by Toru Takahashi, Toshiaki Yujiri, and Yukio Tanizawa

Platelet Antibody Testing in Idiopathic Thrombocytopenic Purpura

Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study by Lori-Ann Linkins,

Next-generation leukemia immunotherapy

An endothelial metronome breast cancer?

Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model by Tobias Tritschler, Marie.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology by Mary Cushman,

T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma by Lotta.

A Systematic Review On Different Prothrombin Complex Concentrate Strategies To Reverse Vitamin K Antagonist Therapy by Nakisa Khorsand, Hilde A.M. Kooistra,

Hypodiploidy With Less Than 45 Chromosomes Confers Adverse Risk in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Cancer Group by.

Tax fingerprint in adult T-cell leukemia

One giant leap for pediatric AMKL

How I treat elderly patients with myeloma

Validation of the Nordic Scoring System for Erythropoietic Stimulating Agents in MDS Using IWG 2006 Erythroid Response Criteria by Jennifer Jayakar, Richard.

Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,

Nonmyeloablative conditioning for relapsed follicular lymphoma

Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.

Skovseth et al. Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo. Blood.

Fusion genes in cord blood

Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism by Sabine Eichinger, Verena Schönauer, Ansgar Weltermann,

Genetic sequence analysis of inherited bleeding diseases

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

by John C. Wood, Pinggao Zhang, Hugh Y

Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein.

Taking a leaf from the book of oral tolerance

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Hepatitis C infection among survivors of childhood cancer

Stage C or not stage C…? by Claire Dearden Blood

ROCK and Rho(ll) in bone marrow

Incidence and Predictors Of Venous Thromboembolism Among Lymphoma Patients In Denmark: A Nationwide Population-Based Cohort Study by Jennifer L Lund, Lene.

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

How I treat cancer-associated venous thromboembolism

by Santosh L. Saraf, Xu Zhang, Tamir Kanias, James P. Lash, Robert E

Venous thromboembolism in chronic lymphocytic leukemia: a Danish nationwide cohort study by Inger Lise Gade, Signe Juul Riddersholm, Ilse Christiansen,

Prevention of hospital-acquired thrombosis from a primary care perspective: a qualitative study by Ian Litchfield, David Fitzmaurice, Patricia Apenteng,

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.

Validation of Venous Clinical Severity Score (VCSS) with other venous severity assessment tools from the American Venous Forum, National Venous Screening.

Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis by Samuel Yamshon,

by H. Ddungu, M. Waiswa, R. Kruisselbrink, P. Kagoma, and M. Crowther

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

Assessment of Hematological Data in a Cohort of European Children with Sickle Cell Anemia Treated with Hydroxyurea: Can European Centers Apply Today the.

Bigger, Stronger, Faster: Chimeric Antigen Receptor T Cells Are Olympic Killers by Paul J Neeson, Alexander James Davenport, Joseph A Trapani, Michael.

TP53 Mutations in AML Predict Adverse Outcome in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant by Bartlomiej M Getta, Arnab Ghosh,

Rituximab immunotherapy: it’s getting personal

Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.

Two run charts showing the effects of Plan, Do, Study, Act cycles on 24-hour Electronic Patient Records venous thromboembolism (EPR VTE) risk assessment.

by Chatree Chai-Adisaksopha, Davide Matino, and Alfonso Iorio

Initial treatment of CLL: integrating biology and functional status

Bland-Altman plot of arterial and central venous blood Pco2 showing the regression line (solid line) and the 95% limits of agreement of −12.3 to 4.8 mmHg.

A fishbone diagram summarising factors contributing to urology inpatients not having a 24-hour Electronic Patient Records venous thromboembolism (EPR VTE)

Cumulative prevalence of venous thromboembolic events in ITP patients who underwent splenectomy compared with those who did not. Cumulative prevalence.

Percentage of inpatients receiving ‘appropriate thromboprophylaxis’ at the hospital. Percentage of inpatients receiving ‘appropriate thromboprophylaxis’

Balancing bleeding in brain metastases

Cold agglutinin disease

Presentation transcript:

A Novel Risk Assessment Model to Predict Venous Thromboembolism (VTE) in Cancer Inpatients: The Canclot Score by Dana E. Angelini, M. Todd Greene, Julie N Wietzke, Scott A Flanders, and Suman L. Sood Blood Volume 128(22):1181-1181 December 2, 2016 ©2016 by American Society of Hematology

Dana E. Angelini et al. Blood 2016;128:1181 ©2016 by American Society of Hematology

Dana E. Angelini et al. Blood 2016;128:1181 ©2016 by American Society of Hematology

Dana E. Angelini et al. Blood 2016;128:1181 ©2016 by American Society of Hematology